Previous studies have shown evidence for the efficacy of the BCL-2 inhibitor venetoclax in BCP-ALL cells [14–16, 32] and clinical data are being collected from case studies [33] and first clinical trials [34] (ClinicalTrials.gov: e.g., NCT03236857). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.